Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
Paola Rogliani,Francesco Cavalli,Alfredo Chetta,Mario Cazzola,Luigino Calzetta
DOI: https://doi.org/10.2147/JAA.S283489
2022-05-07
Journal of Asthma and Allergy
Abstract:Paola Rogliani, 1 Francesco Cavalli, 1 Alfredo Chetta, 2 Mario Cazzola, 1 Luigino Calzetta 2 1 Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; 2 Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy Correspondence: Paola Rogliani, Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, Email Introduction: Inhaled corticosteroid/long-acting β 2 -adrenoceptor agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently recommended as controller option at asthma Step 4 and as preferred treatment at asthma Step 5, but no research investigated the potential drawbacks of this therapeutic option in a large asthmatic population. Thus, the aim of this study was to quantify the potential drawbacks of triple FDC therapy in asthma. Methods: A pairwise meta-analysis was performed according to PRISMA-P guidelines to assess the risk of overall serious adverse events (SAEs), cardiovascular SAEs, and pneumonia reported as SAE in asthmatic patients treated with ICS/LABA/LAMA FDC vs ICS/LABA FDC. A pooled analysis was performed to calculate the frequency of SAEs. Results: Data from 7204 asthmatic patients were extracted from the CAPTAIN, IRIDIUM, TRIMARAN, and TRIGGER studies. Triple FDC vs ICS/LABA FDC did not increase the risk of total SAEs (RR 0.99 95% CI 0.83– 1.18) and cardiac SAEs (RR 0.74 95% CI 0.39– 1.40), whereas the sensitivity analysis performed to resolve heterogeneity resulted in increased risk of vascular SAEs (RR 3.23 95% CI 1.05– 9.90, P< 0.05). The level of ICS dose did not modulate the risk of pneumonia, in any case pneumonia was the most frequent SAE (0.57%). These results were not affected by significant risk of bias. Conclusion: Triple FDC is a safe pharmacological therapy in severe asthmatic patients; it is characterized by a favourable safety profile and few potential drawbacks, namely, the increased risk of vascular SAEs, that certainly are worthy of future investigations. Keywords: asthma, cardiovascular, meta-analysis, pneumonia, safety, triple combination The current Global Initiative for Asthma (GINA, 2021) 1 recommendations suggest to administer as-needed low dose inhaled corticosteroid (ICS)/formoterol fixed-dose combination (FDC) as preferred controller treatment at asthma Step 1 and 2, and low dose maintenance ICS/formoterol FDC as preferred controller treatment at asthma Step 3 in adults and adolescents. 2 The GINA document also recommends to administer ICS/long-acting β 2 -adrenoceptor agonist (LABA)/long-acting muscarinic antagonist (LAMA) FDC as controller option at asthma Step 4 and as preferred treatment at add on asthma Step 5 in adults and adolescents. 2 Effectively, the co-primary endpoints of a large quantitative synthesis of data from randomized controlled trials (RCTs) indicated that triple FDC was significantly effective in preventing the risk of moderate to severe exacerbation and improving lung function. 3 These data were confirmed also by the clinical interpretation of efficacy outcomes in pharmacological studies on triple FDC for uncontrolled asthma, reporting that ICS/LABA/LAMA FDC reached the minimal clinically important difference for the risk of exacerbation, lung function, asthma control, and quality of life not only when compared to ICS/LABA FDC, but often also vs the free triple combination of fluticasone/salmeterol plus tiotropium where the ICS was administered at high dose. 4 Despite the proved therapeutic efficacy of triple FDC in severe asthma, to date only few evidence originated from research specifically performed to assess the safety profile of ICS/LABA/LAMA FDC in a large asthmatic population. 5 Therefore, the aim of this study was to investigate the potential drawbacks of triple FDC therapy in asthma via quantitative synthesis assessing the risk of overall serious adverse events (SAEs), and more specifically the risk of cardiovascular SAEs and pneumonia reported as SAE. This quantitative synthesis has been registered to the international prospective register of systematic reviews (PROSPERO registration ID: CRD42022298742, available at https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=298742 ), and performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). 6 The relative flow diagram is shown in Figure 1. This study satisfied all the recommended items reported by the PRISMA-P checklist ( Table S1 ). 6 < -Abstract Truncated-
immunology,allergy,respiratory system